These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15345501)

  • 1. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
    van Roon EN; Jansen TL; van de Laar MA; Janssen M; Yska JP; Keuper R; Houtman PM; Brouwers JR
    Ann Rheum Dis; 2005 Apr; 64(4):569-74. PubMed ID: 15345501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
    Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
    Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis.
    Chan V; Charles BG; Tett SE
    Br J Clin Pharmacol; 2005 Sep; 60(3):257-64. PubMed ID: 16120064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels.
    Fajardo-Robledo NS; Jacobo-Cuevas H; Perez-Guerrero EE; Corona-Sanchez EG; Saldaña-Cruz AM; Romero-Tejeda EM; Rodriguez-Jimenez NA; Totsuka-Sutto SE; Lopez-Roa RI; Ponce-Guarneros JM; Alcaraz-Lopez MF; Cerpa-Cruz S; Muñoz-Valle JF; Cardona-Muñoz EG; Gonzalez-Lopez L; Gamez-Nava JI;
    Sci Rep; 2022 Feb; 12(1):1877. PubMed ID: 35115601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
    Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
    J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography.
    Schmidt A; Schwind B; Gillich M; Brune K; Hinz B
    Biomed Chromatogr; 2003 Jun; 17(4):276-81. PubMed ID: 12833393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy.
    van Roon EN; Yska JP; Raemaekers J; Jansen TL; van Wanrooy M; Brouwers JR
    J Pharm Biomed Anal; 2004 Sep; 36(1):17-22. PubMed ID: 15351043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leflunomide and malononitrilamides.
    Silva Júnior HT; Morris RE
    Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography.
    Dias VC; Lucien J; LeGatt DF; Yatscoff RW
    Ther Drug Monit; 1995 Feb; 17(1):84-8. PubMed ID: 7725383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leflunomide: a review of its use in active rheumatoid arthritis.
    Prakash A; Jarvis B
    Drugs; 1999 Dec; 58(6):1137-64. PubMed ID: 10651393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats.
    Mehl ML; Tell L; Kyles AE; Chen YJ; Craigmill A; Gregory CR
    J Vet Pharmacol Ther; 2012 Apr; 35(2):139-46. PubMed ID: 21615755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
    Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
    Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection.
    Krisl JC; Taber DJ; Pilch N; Chavin K; Bratton C; Thomas B; McGillicuddy J; Baliga P
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):1003-9. PubMed ID: 22461534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients.
    Kraan MC; de Koster BM; Elferink JG; Post WJ; Breedveld FC; Tak PP
    Arthritis Rheum; 2000 Jul; 43(7):1488-95. PubMed ID: 10902750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
    Magne D; Mézin F; Palmer G; Guerne PA
    Inflamm Res; 2006 Nov; 55(11):469-75. PubMed ID: 17122964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts.
    Migita K; Miyashita T; Ishibashi H; Maeda Y; Nakamura M; Yatsuhashi H; Ida H; Kawakami A; Aoyagi T; Kawabe Y; Eguchi K
    Clin Exp Immunol; 2004 Sep; 137(3):612-6. PubMed ID: 15320915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases.
    Wang J; Sun J; Hu J; Wang C; Prinz RA; Peng D; Liu X; Xu X
    FASEB J; 2020 Aug; 34(8):10132-10145. PubMed ID: 32598086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
    Breedveld FC; Dayer JM
    Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
    Sawamukai N; Saito K; Yamaoka K; Nakayamada S; Ra C; Tanaka Y
    J Immunol; 2007 Nov; 179(10):6479-84. PubMed ID: 17982036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
    Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
    J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.